Yong Kyun Cho

Dr. Yong Kyun Cho


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
SKSeong Hee Kang
Seong Hee Kang
HLHye Won Lee
Hye Won Lee
JYJeong-Ju Yoo
Jeong-Ju Yoo
YCYuri Cho
Yuri Cho
Seung Up KimSeung Up Kim
Seung Up Kim
T(The Korean Association for the Study of the Liver (KASL)
The Korean Association for the Study of the Liver (KASL)

26 December 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
YCYoosoo Chang
Yoosoo Chang
YCYong Kyun Cho
Yong Kyun Cho
YKYejin Kim
Yejin Kim
ESEunju Sung
Eunju Sung
JAJiin Ahn
Jiin Ahn
SRSeungho Ryu
Seungho Ryu

25 February 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
PDF file
SHSang Tae Hwang
Sang Tae Hwang
YCYong Kyun Cho
Yong Kyun Cho
JPJung Ho Park
Jung Ho Park
HKHong Joo Kim
Hong Joo Kim
DPDong Il Park
Dong Il Park
WJWook Jin
Wook Jin
Background and Aims:  Metabolic syndrome and insulin resistance are associated with a higher risk of colon cancer. Non‐alcoholic fatty liver disease (NAFLD) is regarded as a manifestation of metabolic syndrome in the liver. This investigation was initiated to determine whether NAFLD has a relationship to colorectal adenomatous polyps.Methods:  We examined the 2917 participants who underwent a routine colonoscopy at Kangbuk Samsung Hospital in 2007. We divided the 2917 subjects into the adenomatous polyp group (n = 556) and the normal group (n = 2361). Anthropometric measurements, biochemical tests for liver and metabolic function, and abdominal ultrasonographs were assessed.Results:  The prevalence of NAFLD was 41.5% in the adenomatous polyp group and 30.2% in the control group. By multiple logistic regression analysis, NAFLD was found to be associated with an increased risk of colorectal adenomatous polyps (odds ratio, 1.28; 95% confidence interval, 1.03–1.60). An increased risk for NAFLD was more evident in patients with a greater number of adenomatous polyps.Conclusion:  NAFLD was associated with colorectal adenomatous polyps. Further studies are needed to confirm whether NAFLD is a predictor for the development of colorectal adenomatous polyps and cancer.

1 January 2013 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
EJEun Haeng Jeong
Eun Haeng Jeong
DJDae Won Jun
Dae Won Jun
YCYong Kyun Cho
Yong Kyun Cho
YCYoung Gil Choe
Young Gil Choe
SRSeungho Ryu
Seungho Ryu
EJEun Chul Jang
Eun Chul Jang
Jeong EH, et al. Clin Mol Hepatol. 2013 Sep;19(3):266-272. http://dx.doi.org/10.3350/cmh.2013.19.3.266

25 March 2019 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
JYJeong-Ju Yoo
Jeong-Ju Yoo
KKKim Kim
Kim Kim
MKMoon Young Kim
Moon Young Kim
DJDae Won Jun
Dae Won Jun
SKSang Gyune Kim
Sang Gyune Kim
JSJoo Hyun Sohn
Joo Hyun Sohn
Nonalcoholic fatty liver disease (NAFLD), together with metabolic syndrome and obesity, has shown a rapid increase in prevalence worldwide and is emerging as a major cause of chronic liver disease and liver transplantation. Among the various phenotypes of NAFLD, nonalcoholic steatohepatitis (NASH) is highly likely to progress to development of end-stage liver disease and cardiometabolic disease, resulting in liver-related and non-liver-related mortality. Nonetheless, there is no standardized pharmacotherapy against NASH and many drugs are under development in ongoing clinical trials. To develop a successful anti-NASH drug, it is necessary to select an appropriate target population and treatment outcomes depending on whether the mode of action is anti-metabolic, anti-inflammatory or anti-fibrotic. Recently, innovative surrogate markers have been investigated to replace hard outcomes such as liver histology and mortality and reduce the clinical trial duration. Currently, several drugs with fast track designation are being tested in phase III clinical trials, and many other drugs have moved into phase II clinical trials. Both lean NAFLD and typical obese NAFLD have been extensively studied and genetic variants such as PNPLA3 and TM6SF2 have been identified as significant risk factors for lean NAFLD. In the near future, noninvasive biomarkers and effective targeted therapies for NASH and associated fibrosis are required to develop precision medicine and tailored therapy according to various phenotypes of NAFLD.

15 June 2010 in Internal Medicine Journal
Verified
Journal Article
Closed access
PDF file
SHS. T. Hwang
S. T. Hwang
YCYong Kyun Cho
Yong Kyun Cho
JYJ. W. Yun
J. W. Yun
JPJ. H. Park
J. H. Park
HKH. J. Kim
H. J. Kim
WJW. Jin
W. Jin